CompletedNot Applicable

A Novel Approach to Antimicrobial Resistance: Machine Learning Predictions for Carbapenem-Resistant Klebsiella in ICUs

Turkey (Türkiye)289 participantsStarted 2023-12-01

Plain-language summary

The aim of this study to predict carbapenem resistant Klebsiella spp. earlier in our patients monitored in our Intensive Care Unit in the future, using artificial intelligence. Patients with bloodstream infection and pneumonia caused by Klebsiella spp. will be comparatively examined in two groups, as sensitive and resistant. Resistance will be attempted to be predicted with deep machine learning.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients monitored in our third-level intensive care unit between June 2017 and June 2023 will be evaluated retrospectively. Patients with pneumonia and bloodstream infection developed with Klebsiella spp. will be included in the study. Exclusion Criteria: * Patients under the age of 18 have not been included in the study. * Infections outside of the respiratory tract and bloodstream have not been included in the study. * Patients with respiratory tract colonization and without active inflammation have also not been included.

What they're measuring

Risk of Carbapenem Resistant Klebsiella Infection

Timeframe: 3 months

Trial details

NCT IDNCT05985057

SponsorKocaeli University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06-22

View on ClinicalTrials.gov More Carbapenem Resistant Enterobacteriaceae Infection trials